Skip to main content

Integrated Diagnostics for Prostate Cancer

Project description

Artificial intelligence to support early prostate cancer diagnostics

Prostate cancer is the most common type of cancer in men and their second leading cause of death; however, it is highly treatable in the early stages. Recent studies and clinical trials have demonstrated the efficiency of prostate MRI in early diagnosis, with 5 times less missed cancer cases and 25 % fewer biopsies. Care standards now recommend MRI prior to every biopsy, leading to an increased demand for prostate MRI scans. Conventional radiology reading capacity cannot keep pace with the demand. Quantib BV (Netherlands) developed an AI-enhanced integrated diagnostic solution for the detection of potential tumors and workflow optimization involving urologists, radiologists and pathologists. The current EU-funded ID-PROSTATE project allows further improvement and acceleration focusing on product commercialization.

Field of science

  • /medical and health sciences/clinical medicine/cancer/prostate cancer
  • /engineering and technology/medical engineering/diagnostic imaging/magnetic resonance imaging

Call for proposal

H2020-EIC-SMEInst-2018-2020-3
See other projects for this call

Funding Scheme

SME-2b - SME Instrument (grant only and blended finance)

Coordinator

QUANTIB BV
Address
Westblaak 106
3012KM Rotterdam
Netherlands
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 100 371,88